Impact of change in vancomycin-resistant Enterococcus infection prevention policy

Infect Control Hosp Epidemiol. 2024 May;45(5):691-692. doi: 10.1017/ice.2023.297. Epub 2024 Jan 22.

Authors

Christopher R Kiss^{1

2}, Susan Ryan¹, Jacky Meyer¹, Despina Kotsanas², Allen C Cheng^{2

3}, Rhonda L Stuart^{1

3}

Affiliations

¹ Department of Infection Prevention and Epidemiology, Monash Health, Clayton, Victoria, Australia.
² Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
³ Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.

PMID: 38251664
DOI: 10.1017/ice.2023.297

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use
Bacterial Infections* / drug therapy
Cross Infection* / drug therapy
Enterococcus
Enterococcus faecium*
Gram-Positive Bacterial Infections* / prevention & control
Humans
Policy
Vancomycin
Vancomycin-Resistant Enterococci*

Substances

Vancomycin
Anti-Bacterial Agents